Paul N. Jensen

Paul N. Jensen

Auto-generated profile, based on publicly available information

Paul N. Jensen

Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2012 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
PJPaul N. Jensen
Paul N. Jensen
KJKarin Johnson
Karin Johnson
JFJames Floyd
James Floyd
SHSusan R. Heckbert
Susan R. Heckbert
RCRyan Carnahan
Ryan Carnahan
SDSascha Dublin
Sascha Dublin
Purpose: The objectives of this study were to characterize the validity of algorithms to identify AF from electronic health data through a systematic review of the literature and to identify gaps needing further research.Methods: Two reviewers examined publications during 1997–2008 that identified patients with atrial fibrillation (AF) from electronic health data and provided validation information. We abstracted information including algorithm sensitivity, specificity, and positive predictive value (PPV).Results: We reviewed 544 abstracts and 281 full‐text articles, of which 18 provided validation information from 16 unique studies. Most used data from before 2000, and 10 of 16 used only inpatient data. Three studies incorporated electronic ECG data for case identification or validation. A large proportion of prevalent AF cases identified by ICD‐9 code 427.31 were valid (PPV 70%–96%, median 89%). Seven studies reported algorithm sensitivity (range, 57%–95%, median 79%). One study validated an algorithm for incident AF and reported a PPV of 77%.Conclusions: The ICD‐9 code 427.31 performed relatively well, but conclusions about algorithm validity are hindered by few recent data, use of nonrepresentative populations, and a disproportionate focus on inpatient data. An optimal contemporary algorithm would likely draw on inpatient and outpatient codes and electronic ECG data. Additional research is needed in representative, contemporary populations regarding algorithms that identify incident AF and incorporate electronic ECG data. Copyright © 2012 John Wiley & Sons, Ltd.

1 November 2018 in Journal of Electrocardiology
Verified
Journal Article
Closed access
SHSusan R. Heckbert
Susan R. Heckbert
TAThomas R. Austin
Thomas R. Austin
PJPaul N. Jensen
Paul N. Jensen
JFJames S. Floyd
James S. Floyd
BPBruce M. Psaty
Bruce M. Psaty
RKRichard A. Kronmal
Richard A. Kronmal

18 February 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
PJPaul N. Jensen
Paul N. Jensen
AFAmanda M. Fretts
Amanda M. Fretts
AHAndrew N. Hoofnagle
Andrew N. Hoofnagle
CSColleen M. Sitlani
Colleen M. Sitlani
BMBarbara McKnight
Barbara McKnight
RLRozenn N. Lemaitre
Rozenn N. Lemaitre
Background: Ceramides exhibit multiple biological activities that may influence the pathophysiological characteristics of atrial fibrillation (AF). Whether the length of the saturated fatty acid carried by the ceramide or their sphingomyelin precursors are associated with AF risk is not known. Methods and Results: Among 4206 CHS (Cardiovascular Health Study) participants (mean age, 76 years; 40% men) who were free of prevalent AF at baseline, we identified 1198 incident AF cases over a median 8.7 years of follow‐up. We examined 8 sphingolipid species: ceramide and sphingomyelin species with palmitic acid and species with very‐long‐chain saturated fatty acids: arachidic; behenic; and lignoceric. In adjusted Cox regression analyses, ceramides and sphingomyelins with very‐long‐chain saturated fatty acids were associated with reduced AF risk (ie, per 2‐fold higher ceramide with behenic acid hazard ratio, 0.71; 95% CI, 0.59–0.86; sphingomyelin with behenic acid hazard ratio, 0.60; 95% CI, 0.46–0.77). In contrast, ceramides and sphingomyelins with palmitic acid were associated with increased AF risk (ceramide with palmitic acid hazard ratio, 1.31; 95% CI, 1.03–1.66; sphingomyelin with palmitic acid hazard ratio, 1.73; 95% CI, 1.18–2.55). Associations were attenuated with adjustment for NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), but did not differ significantly by age, sex, race, body mass index, or history of coronary heart disease. Conclusions: Our findings suggest that several ceramide and sphingomyelin species are associated with incident AF, and that these associations differ on the basis of the fatty acid. Ceramides and sphingomyelins with palmitic acid were associated with increased AF risk, whereas ceramides and sphingomyelins with very‐long‐chain saturated fatty acids were associated with reduced AF risk.

1 May 2020 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
AFAmanda Fretts
Amanda Fretts
PJPaul N Jensen
Paul N Jensen
AHAndrew Hoofnagle
Andrew Hoofnagle
BMBarbara McKnight
Barbara McKnight
BHBarbara V Howard
Barbara V Howard
RLRozenn N Lemaitre
Rozenn N Lemaitre
Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans. We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies. The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes. There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (μM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk. Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134.

1 March 2019 in EBioMedicine
Verified
Journal Article
Open access
PJPaul N. Jensen
Paul N. Jensen
AFAmanda M. Fretts
Amanda M. Fretts
CYChaoyu Yu
Chaoyu Yu
AHAndrew N. Hoofnagle
Andrew N. Hoofnagle
JUJason G. Umans
Jason G. Umans
RLRozenn N. Lemaitre
Rozenn N. Lemaitre
Animal studies suggest sphingolipids as an early marker of impaired glucose metabolism; however, research in humans is limited. We evaluated whether individual sphingolipid species were associated with fasting plasma glucose and incident impaired fasting glucose in a longitudinal cohort study. We measured 15 sphingolipid species from blood samples collected in 2001-2003 from 2145 participants without prevalent diabetes in the Strong Heart Family Study. Fasting plasma glucose was measured in blood samples collected at baseline and follow-up (mean 5.5 years after baseline). The average age of study participants was 38 years; 41% were men. Ceramide, sphingomyelin, and glucosylceramide species levels were higher in older participants; lactosyl-ceramide levels were higher in participants with lower BMIs. In adjusted analyses, greater concentrations of most ceramide species and lower lactosyl-ceramide with palmitic acid (LC-16) were associated with higher glucose levels at baseline. We did not observe associations of sphingomyelin species or glucosyl-ceramide species with glucose levels. Associations of sphingolipid levels with fasting glucose levels at follow-up were similar but had greater uncertainty than associations with baseline glucose. Although no statistically significant associations of sphingolipids with incident impaired fasting glucose were present, results were similar to glucose analyses. We identified several ceramide species associated with higher fasting glucose levels and one sphingolipid, LC-16, that was associated with lower fasting glucose levels. These findings compliment previous research, which linked these sphingolipids with fasting insulin levels, and suggest that higher levels of these ceramides and lower LC-16 may be an early marker of impaired glucose metabolism. FUND: US National Institutes Health.

15 January 2013 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
PJPaul N. Jensen
Paul N. Jensen
ETEvan L. Thacker
Evan L. Thacker
SDSascha Dublin
Sascha Dublin
BPBruce M. Psaty
Bruce M. Psaty
SHSusan R. Heckbert
Susan R. Heckbert